oral cancer – Page 23 – Oral Cancer News

Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability?

Source: PubMed.gov BACKGROUND: Human papillomavirus (HPV) vaccine is now approved for use in males in the United States to prevent genital warts. We conducted an experiment to see whether framing HPV vaccination as also preventing cancer in men would increase men's vaccination willingness. METHODS: We conducted an online survey in January 2009 with a national sample of men ages 18 to 59 years who self-identified as gay/bisexual (n = 312) or heterosexual (n = 296). In the within-subjects experiment, men read four randomly ordered vignettes that described hypothetical vaccines that prevented either genital warts alone, or genital warts and either anal cancer, oral cancer, or penile cancer. We analyzed data using repeated measures ANOVA and tested whether perceived severity or perceived likelihood mediated the effect of disease outcome framing on men's HPV vaccination willingness. RESULTS: Although only 42% of men were willing to receive HPV vaccine when it was framed as preventing genital warts alone, 60% were willing to get it when it was framed as preventing cancer in addition to genital warts (P < 0.001). The effect of outcome framing was the same for heterosexual and gay/bisexual men and for the three cancer types examined. Perceived severity of disease partially mediated the association between disease outcome and HPV vaccination willingness. CONCLUSIONS: Men may be more accepting of HPV vaccine when it is framed as preventing cancer, regardless which of the three most common HPV-related cancers in men is described. IMPACT: Study findings may be useful in developing health communication messages that maximize HPV vaccine [...]

Oral Cancer Foundation News Team - A2010-11-08T13:52:28-07:00November, 2010|Oral Cancer News|

Superselective intra-arterial chemoradiotherapy with docetaxel-nedaplatin for advanced oral cancer.

Source: PubMed.gov Cisplatin-based, superselective, intra-arterial chemotherapy concurrent with radiotherapy (SSIACRT) has gained wide acceptance as a common/curative treatment for advanced head and neck cancer. We combined nedaplatin (CDGP) with docetaxel (DOC) as a new combination in SSIACRT for advanced oral squamous cell carcinoma in 2003. Twenty-two patients with advanced oral cancer were treated by radiotherapy (66Gy) concurrent with superselective intra-arterial DOC (40mg/body) and CDGP (80mg/m(2)) infusion between 2003 and 2009. Complete response was achieved in 18 (81.8%) of the 22 patients. Of the 17 patients with positive neck disease, 16 (94%) were assessed as disease-free. The 5-year overall survival rate was 78.5%, and the major adverse effects were leukocytopenia and mucositis. Five patients (22.7%) developed distant metastases post-treatment. These results indicate that intra-arterial docetaxel-nedaplatin infusion concurrent with radiotherapy is efficacious for advanced oral cancer. The side effects are easily manageable, and the most important outcome of the treatment is the preservation of patients' quality of life (QOL) and improved prognosis.

Oral Cancer Foundation News Team - A2010-11-08T13:13:31-07:00November, 2010|Oral Cancer News|

Oral Cancer screening draws hundreds

Volunteer prosthodontists and oral surgeons, in conjunction with UCF’s Department of Communication Sciences and Disorders and Pre-Dental Society, conducted hundreds of free oral cancer screenings during a Nov. 3 outreach event held near the Student Union. “Our students and the doctors screened approximately 400 students, staff and faculty over six hours,” said Bari Hoffman-Ruddy, associate professor of communication sciences and disorders. “This is a record for us and the American College of Prosthodontist’s annual screening program.” The ACP is particularly interested in targeting a younger population for screenings because of the association between human papillomavirus (HPV) infection and oral cancer. According to the ACP, 25 percent of those newly diagnosed with oral cancer have no traditional risk factors, such as the use of tobacco or alcohol. “Much of the literature suggests a strong association between transmission of HPV via oral sex, and this is a relatively new demographic with oral cancer,” said Dr. John Whitsitt, a prosthodontist and ACP member from Daytona Beach who volunteered at the event. Students and faculty members worked at tables outside a large bus devoted to the screenings. They shared information about risk factors associate with oral cancer and encouraged people to have a free screening performed by a volunteer specialist. Each screening took just a few minutes. As of 1 p.m., no cases of oral cancer had been detected, said Whitsitt, who was clearly pleased with the turnout. ”But it’s just so important to increase awareness about it.”

Oral Cancer Foundation News Team - A2010-11-07T08:23:09-07:00November, 2010|Oral Cancer News|

Oral cancer test’s value unproven

Source: Boston.com By: Neil Munshi The usual dental checkup goes something like this: lean back, open wide, avoid flinching, rinse, spit. But in addition to looking for cavities, dentists are increasingly checking for oral cancer, too - and not just by peering and probing. A relatively new screening tool allows dentists to better gauge whether a patient is in the early stages of oral cancer by looking at the mouth under a special light. But the test may be overused, and it's not yet clear whether it justifies its price tag. A review of studies of the devices published in this month's Journal of the American Dental Association concluded that for low-risk patients, there is "insufficient evidence to support or refute the use of visually based examination" devices, such as the ViziLite. Still, roughly 10 to 15 percent of the 100,000 practicing dentists in the United States offer ViziLite or a similar scan, which some credit with helping them better identify lesions in the mouth than simply looking with the naked eye. "Frankly, I've seen stuff I would normally just have glossed over and it doesn't hurt to take a second look . . . at something that might not normally be looked at - that might save somebody's life," said Dr. Anjum A. Ansari, a downtown Boston dentist, who charges her patients $80 for the service. Insurance has only covered the scan for one of her patients, Ansari said. That $80 is the test's only actual advantage, said Dr. [...]

Oral Cancer Foundation News Team - A2010-11-04T09:40:53-07:00November, 2010|Oral Cancer News|

The Most Deadly HPVs in the World

Source: WebMD News Author: Daniel DeNoon Cervical Cancer-Causing Viruses ID'd in Worldwide Study Oct. 19, 2010 – Two human papillomavirus types included in HPV vaccines cause 71% of cervical cancers -- but there are six other cervical cancer-causing HPVs, an international study finds. Led by Spanish researcher Silvia de Sanjose, MD, the effort analyzed 22,661 tissue samples from 14,249 women from 38 countries in six continents. Researchers looked for any of the 118 known types of HPV. The samples included 10,575 cases of invasive cervical cancer -- for women, the second most common cancer in the world. HPV is believed to cause nearly all cervical cancers. Although the study detected HPV in only 85% of cervical cancers, de Sanjose and colleagues suggest that various problems (such as DNA degradation in samples) led researchers to miss HPV in the remaining 15% of cases. There are currently two HPV vaccines: Cervarix from GlaxoSmithKline and Gardasil from Merck. Both protect against HPV types 16 and 18; Gardasil also protects against the genital wart-causing HPV strains 6 and 11. The new study strongly supports use of these vaccines, as HPV 16 and HPV 18 account for 71% of invasive cervical cancers. HPV 16, HPV 18, and HPV 45 are found in 94% of cervical adenocarcinomas. HPV types 18 and 45 are found in much younger women with invasive cervical cancer, suggesting that these viruses are particularly deadly. HPV 16 is also linked to cancer in younger women. In addition to HPV 16, 18, and [...]

Charlotte Parker2010-10-26T12:24:24-07:00October, 2010|Oral Cancer News|

Health Risks of Oral Sex- linked to Oral Cancer

Source: Women's Health Magazine Author: Alyssa Giacobbe Long known to cause cervical cancer, the pervasive but often silent human papillomavirus (HPV) has been finding its way into women's mouths Mische Eddins, 37, awoke with a head cold. Or what seemed like one anyway. Postnasal drip. Sore throat. Swollen lymph nodes. No biggie—it was the fall of 2007, and a seasonal bug was winding its way through Seattle. "I had just been bragging to my friends about how I'd managed to avoid getting sick," she says. "But I was healthy, so it all passed quickly." Everything, that is, except a swollen node on the left side of her neck, which, months later, hadn't gone away. Christmastime came, and the little bump was still there. Sans appointment, Mische walked into her doctor's office and left with a script for antibiotics. No improvement. She then bounced from M.D. to M.D., and finally, six months after that seemingly innocuous head cold, she had a PET/CT scan. The results were a total shock: Mische had stage III oral cancer, and the disease had spread from her tonsil to her lymph nodes. Within hours, her docs had scheduled a tonsillectomy and were talking about chemo and radiation. Someone suggested she prepare a will. "I was floored," she says. "A will?" A professional singer, Mische exercised almost every day, ate a mostly organic diet, didn't booze heavily, and never smoked as an adult. Even her doctors were stymied. Searching for answers, one physician tested Mische's cancer cells [...]

Charlotte Parker2010-10-26T10:04:27-07:00October, 2010|Oral Cancer News|

HPV Causing “Slow Epidemic” of Oral Cancers

Source: Medscape Today By: Janis C. Kelly October 21, 2010 — Human papillomavirus (HPV) is a risk factor for oropharyngeal squamous cell carcinoma (OSCC), and might account for the steady increase in OSCC incidence, even in subjects who do not smoke or consume alcohol, according to Swedish researchers. A review of recent studies, conducted by Trobjorn Ramqvist, MD, and Tina Dalianis, MD, PhD, and published online October 13 in Emerging Infectious Diseases, suggests that changes in sexual practices are behind the surge in OSCC cases linked to sexually transmitted HPV. The key factors appear to be multiple sex partners, starting sexual activity at a younger age, and increased oral sex. The data are startling. For example, from 1970 to 2002, tonsillar cancer (which is the most common OSCC) increased in Stockholm, Sweden, by 2.8-fold, and by 2006/07, 93% of all tonsillar cancers in that city were HPV-positive. Dr. Dalianis, who is professor of tumor virology and the head of the Department of Oncology–Pathology at Karolinska Institutet in Stockholm, told Medscape Medical News that "we realized that there was an increase in HPV-induced tonsillar cancer, but we did not realize it was so eminent until we separated the 2 groups (HPV-negative and -positive tonsillar cancer cases) the way we did." The most common OSCC is tonsillar cancer, followed by base of tongue cancer. Overall 5-year survival for OSCC is about 25%, and HPV-positive OSCC generally has better clinical outcomes than HPV-negative disease. Dr. Dalianis said that HPV (most commonly type 16) [...]

Oral Cancer Foundation News Team - A2010-10-22T11:17:11-07:00October, 2010|Oral Cancer News|

Penthouse Founder Bob Guccione Dead at 79

Source: ThirdAge News Penthouse founder Bob Guccione died on Wednesday in Texas after a long bout with lung cancer, his family said. He was 79 years old. Guccione also suffered from oral cancer, the Oral Cancer Foundation says. “My cancer was only a tiny tumor about the size of an almond at the base of my tongue,” he explained in an intervie with New York Magazine. “The cure is probably every bit as bad as the disease. It’s affected my ability to swallow . . . the mobility of my tongue . . . it makes it very difficult for me to talk...” The Wall Street Journal reported his family said in a statement Guccione died at Plano Specialty Hospital in Plano. Guccione created Penthouse in 1965, immediately setting it apart from Hugh Hefner's Playboy magazine through its more graphic photos of unclothed women and less reliance on the written word. If Playboy was the publishing world's version of the Beatles, Penthouse was the Rolling Stones. "Unlike his future arch-rival Hugh Hefner, he did not suffer from sexual shyness and repression," John Heidenry, a former Penthouse Forum editor wrote in his book "What Wild Ecstasy." "He liked girls, pure and simple, like any average healthy Italian boy from New Jersey, and he was no virgin." Guccione diversified into other magazines, movies and other ventures and his fortune at one time was estimated at $400 million but Penthouse's popularity waned with the advent of Internet pornography.

Oral Cancer Foundation News Team - A2010-10-22T08:48:47-07:00October, 2010|Oral Cancer News|

Dead man will be remembered for spreading oral cancer

Source: The Gawker/ WSJ Author: Steven Miller Louis Bantle, the former marketing director and chairman of U.S. Tobacco, died earlier this month at the age of 81 from emphysema and lung cancer. Bantle was most famous for convincing millions of teenagers to dip. The WSJ chroniclesBantle's work from the 1960s through the 1990s, during which time he helped turn snuff into a billion-dollar business and tripled its use among 18-24 year-olds. "We must sell the use of tobacco in the mouth and appeal to young people," he said, according to the minutes of a marketing meeting in 1968. "We hope to start a fad." "If you go to high school in Texas and you don't have a can of snuff in your pocket, you're out," Mr. Bantle told Forbes in 1980. Your legacy will live on, Mr. Bantle. Original Article from the WSJ: Louis Bantle made dipping snuff into a national pastime. Mr. Bantle, who died Oct. 10 at age 81 after a long struggle with lung cancer and emphysema, was chairman of United States Tobacco Co. for two decades beginning in 1973, a period that saw an explosion in snuff's popularity, particularly among younger users. In the 1970s, sales of the company's Skoal and Copenhagen tobaccos were relatively small and concentrated in the upper Midwest, where Scandinavian woodcutters had spread the smokeless habit in the 19th century. Mr. Bantle ramped up advertising featuring football and rodeo star Walt Garrison and other rugged athletes. He introduced a series of "starter" [...]

Charlotte Parker2010-10-20T08:39:52-07:00October, 2010|Oral Cancer News|

Dentistry’s Schmidt and Boston Biomedical Share $1.25mil NIH Grant for Cancer Pain Research

Source: Iewy Author: Staff The National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH), has awarded a joint, five-year, $1.25 million grant to Dr. Brian L. Schmidt, a Professor of Oral and Maxillofacial Surgery at the NYU College of Dentistry, and Dr. Markus Hardt, a protein chemist at the Boston Biomedical Research Institute, for a study of the molecular mechanisms of oral cancer pain. The ultimate goal of the research is to spur the development of more sophisticated analgesics (pain medications) to alleviate the pain that is so often manifested in patients with oral cancer. “Oral cancer is a logical place to start when seeking clues about cancer pain,” Dr. Schmidt said. “To begin, oral cancer is very painful. In fact, pain is the most common presenting symptom associated with this cancer. Secondly, oral cancer is painful at the primary site, not just at sites of metastasis as is the case in almost all other cancers. Lastly, the primary site of the oral cancer is readily accessible, enabling us to directly sample the cancer microenvironment.” Dr. Schmidt hypothesizes that the cause of oral cancer pain and pain generated by other cancers may be produced along similar molecular pathways in the body. Oral cancer pain, like many other kinds of cancer pain, is triggered by specific actions. Just as oral cancers can cause patients to feel pain in the oral cavity when they speak, other cancers generate pain during mechanical stimulation. For example, if a [...]

Charlotte Parker2010-10-18T14:53:54-07:00October, 2010|Oral Cancer News|